Compounds > 5-nitro-2-phenyl-1,3-benzoxazole
Page last updated: 2024-12-09

5-nitro-2-phenyl-1,3-benzoxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID759401
CHEMBL ID391351
CHEBI ID105814
SCHEMBL ID2243126
SCHEMBL ID14103583

Synonyms (28)

Synonym
CBMICRO_021228
5-nitro-2-phenyl-1,3-benzoxazole
benzoxazole, 5-nitro-2-phenyl-
OPREA1_504039
5-nitro-2-phenyl-benzooxazole
AE-641/30196036
smr000282830
MLS000856085
BIM-0021399.P001
CHEBI:105814
CHEMBL391351
AKOS000635027
HMS2689K13
CCG-8910
891-43-0
5-nitro-2-phenylbenzoxazole
2-phenyl-5-nitrobenzoxazole
PBRISAFILDFQFS-UHFFFAOYSA-N
mfcd00603147
SCHEMBL2243126
SCHEMBL14103583
Q27183596
sr-01000389400
SR-01000389400-1
DTXSID40353946
5-nitro-2-phenylbenzo[d]oxazole, aldrichcpr
5-nitro-2-phenylbenzo[d]oxazole
CS-0207239
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency2.68550.007215.758889.3584AID588342
Nrf2Homo sapiens (human)Potency3.16230.09208.222223.1093AID624171
BRCA1Homo sapiens (human)Potency3.16230.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency7.14970.004110.890331.5287AID504466; AID504467
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency2.23870.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency6.51310.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency2.23870.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
VprHuman immunodeficiency virus 1Potency1.00001.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency15.84890.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID352099Antimicrobial activity against multidrug-resistant Candida albicans isolates after 24 to 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352090Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352097Antimicrobial activity against multidrug-resistant Staphylococcus aureus after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352093Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID294243Antifungal activity against Candida albicans by serial dilution method2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
QSAR analysis for heterocyclic antifungals.
AID352095Antimicrobial activity against ceftriazone-resistant Bacillus subtilis after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352089Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352092Antimicrobial activity against multidrug-resistant Escherichia coli after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352094Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352091Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352098Antimicrobial activity against Candida albicans ATCC 10231 after 24 to 48 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
AID352096Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.0510conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.05103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
ampicillin trihydrate
[no description available]		2.0510hydrate
witisol
witisol: sunscreen agent linked with contact dermatitis; structure given in first source		2.0510
4-(2-oxazolo[4,5-b]pyridinyl)aniline
[no description available]		2.03101,3-oxazoles
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0510antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
gentamicin sulfate
[no description available]		2.0510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.0510cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510